ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03701763
Recruitment Status : Not yet recruiting
First Posted : October 10, 2018
Last Update Posted : November 16, 2018
Sponsor:
Information provided by (Responsible Party):
Celgene

Brief Summary:

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis.

At least 230 pediatric subjects (ages 6 through 17 years) will be randomized 2:1 to receive either apremilast or placebo for the first 16 weeks and then all subjects will receive apremilast during the 36 week Extension Phase for a total of 52 weeks. Randomization to apremilast arm or placebo arm will be stratified by age group (6 to 11 years or 12 to 17 years). Subjects will receive apremilast treatment of either 20 mg twice daily (BID) or 30 mg BID, depending on weight. This Phase 3 study is being conducted to evaluate the safety and efficacy of apremilast in the treatment of pediatric subjects.


Condition or disease Intervention/treatment Phase
Psoriasis Drug: Apremilast (CC-10004) Other: Placebo Phase 3

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Detailed Description:
Treatment will be assigned by weight with subjects 20 kg to < 50 kg receiving apremilast 20 mg BID or placebo BID and subjects ≥ 50 kg receiving apremilast 30 mg BID or placebo BID. Total study duration is up to 71 weeks. Subjects completing all 52 weeks of the treatment and extension phase will be able to enter the Long-term study. Subjects not entering the Long-term study will return for 3 observational follow-up visits, 4, 8 and 14 weeks after last dose of study drug.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 230 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Estimated Study Start Date : November 15, 2018
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : August 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Apremilast

Arm Intervention/treatment
Experimental: Administration of Apremilast (CC-10004) - 20mg
Apremilast 20mg Twice Daily (BID)
Drug: Apremilast (CC-10004)
Apremilast (CC-10004)

Experimental: Administration of Apremilast (CC-10004) - 30mg
Apremilast 30mg Twice Daily (BID)
Drug: Apremilast (CC-10004)
Apremilast (CC-10004)

Placebo Comparator: Administration of Placebo
Placebo tablet Twice Daily (BID)
Other: Placebo
Placebo




Primary Outcome Measures :
  1. Proportion of subjects with an sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline [ Time Frame: Up to week 16 ]
    The sPGA is the assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation.


Secondary Outcome Measures :
  1. Proportion of subjects who achieve at least a 75% reduction in PASI (PASI-75) from baseline [ Time Frame: Up to week 16 ]
    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI is a validated instrument that has become standard in clinical trials for psoriasis.

  2. Proportion of subjects who achieve at least a 50% reduction in PASI (PASI-50) from baseline [ Time Frame: Up to week 16 ]
    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI is a validated instrument that has become standard in clinical trials for psoriasis.

  3. Percent change from baseline in total PASI score [ Time Frame: Up to week 16 ]
    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI is a validated instrument that has become standard in clinical trials for psoriasis.

  4. Percent change from baseline in affected Body Surface Area (BSA) [ Time Frame: Up to week 16 ]
    BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the subject's hand, which equates to approximately 1% of total body surface area.

  5. Proportion of subjects who achieve CDLQI (0/1) [ Time Frame: Up to week 16 ]
    The CDLQI is designed to measure the impact of skin disease on children's quality of life.

  6. Change from baseline in CDLQI score [ Time Frame: Up to week 16 ]
    The CDLQI is designed to measure the impact of skin disease on children's quality of life.

  7. Adverse Events (AEs) [ Time Frame: From enrollment until at least 28 days after completion of study treatment ]
    Number of subjects with adverse event

  8. Stool Diary [ Time Frame: From Baseline up to week 56 ]
    Symptoms of bowel movement will be collected using a daily stool diary

  9. Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: From Baseline up to Week 52 ]
    Questionnaire designed to determine any risk of self-harm by the study subject

  10. Tanner Stages [ Time Frame: At Baseline and week 52 ]
    Tanner Stages is a scale defining physical measurements of sexual development based on external primary and secondary sex characteristics

  11. Psoriasis disease flare [ Time Frame: From Baseline up to week 52 ]
    Proportion of subjects with sudden intensification of psoriasis (new generalized erythrodermic, inflammatory or pustular psoriasis) requiring medical intervention beyond allowable medications

  12. Psoriasis Rebound [ Time Frame: 4 week follow-up, 8 week follow-up, and 14 week follow-up visits ]
    Severe and sudden worsening of disease (PASI ≥ 125% of baseline or new generalized, pustular, erythrodermic psoriasis) after treatment has been discontinued

  13. Height Measurement [ Time Frame: Up to week 66 ]
    Height is measured and recorded at each visit

  14. Weight Measurement [ Time Frame: Up to week 66 ]
    Weight is measured and recorded at each visit



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or female subjects 6 to 17 years of age, inclusive, at the time the informed consent form is signed by the legal guardian
  2. Subjects must have a weight of ≥ 20 kg
  3. Diagnosis of chronic plaque psoriasis for at least 6 months prior to Screening.
  4. Has moderate to severe plaque psoriasis at Screening and Baseline as defined by:

    • PASI score ≥ 12; and
    • Body surface area (BSA) ≥ 10%; and
    • sPGA ≥ 3 (moderate to severe)
  5. Disease inadequately controlled by or inappropriate for topical therapy for psoriasis
  6. Candidate for systemic therapy or phototherapy

Exclusion Criteria:

  1. Guttate, erythrodermic, or pustular psoriasis at Screening and Baseline
  2. Psoriasis flare or rebound within 4 weeks prior to Screening
  3. Prior history of suicide attempt at any time in the subject's lifetime prior to Screening or randomization in the study, or major psychiatric illness requiring hospitalization within 3 years prior to signing the assent and informed consent
  4. Answer "Yes" to any question on the Columbia-Suicide Severity Rating Scale during Screening or at Baseline
  5. Current or planned concurrent use of the following therapies that may have a possible effect on psoriasis

    a. Topical therapy within 2 weeks prior to randomization (including but not limited to topical corticosteroids, topical retinoid or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol)

    Exceptions*:

    i. Low potency or weak corticosteroids (please refer to the Investigators' Manual) will be allowed as background therapy for treatment of the face, axillae and groin in accordance with manufacturer's suggested usage ii. Unmedicated skin moisturizer (eg, Eucerin®) will also be permitted for body lesions

    *Subjects should not use these topical treatments within 24 hours prior to the clinic visit.

    b. Conventional systemic therapy for psoriasis within 4 weeks prior to randomization c. Phototherapy treatment (ie, ultraviolet B [UVB], PUVA) within 4 weeks prior to randomization d. Biologic therapy within 4 weeks prior to randomization or 5 PK/PD half-lives (whichever is longer).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03701763


Contacts
Contact: Associate Director Clinical Trial Disclosure 1-888-260-1599 clinicaltrialdisclosure@celgene.com

Sponsors and Collaborators
Celgene
Investigators
Study Director: Wendy Zhang, MD Celgene

Responsible Party: Celgene
ClinicalTrials.gov Identifier: NCT03701763     History of Changes
Other Study ID Numbers: CC-10004-PPSO-003
U1111-1219-3112 ( Registry Identifier: WHO )
2018-002918-12 ( EudraCT Number )
First Posted: October 10, 2018    Key Record Dates
Last Update Posted: November 16, 2018
Last Verified: November 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Celgene:
Pediatric
6 through 17 years
Plaque Psoriasis
Psoriasis
CC-10004
Apremilast
Otezla
Children
Adolescents
SPROUT

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Apremilast
Thalidomide
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Immunosuppressive Agents
Immunologic Factors
Leprostatic Agents
Anti-Bacterial Agents
Anti-Infective Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents